Tretinoin
- Generic Name
- Tretinoin
- Brand Names
- Altreno, Atralin, Biacna, Refissa, Renova, Retin-A, Stieva-A, Tri-luma, Twyneo, Veltin, Vesanoid, Ziana
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28O2
- CAS Number
- 302-79-4
- Unique Ingredient Identifier
- 5688UTC01R
- Background
Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, ...
- Indication
Oral tretinoin is indicated for induction of remission in adults and pediatric patients one year of age and older with acute promyelocytic leukemia (APL), characterized by the presence of t(15;17) translocation or presence of PML/RARα gene expression and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-base...
- Associated Conditions
- Acne Vulgaris, Alopecia, Cornification and dystrophic skin disorders, FAB classification M3 Acute promyelocytic leukemia, Fine Wrinkles, Photodamaged Skin, Skin hyperpigmentation, Keratinization disorders of the feet, Keratinization disorders of the hand, Moderate Melasma, Mottled hyperpigmentation, Severe Melasma, Severe, recalcitrant Cystic acne, Tactile roughness of facial skin
- Associated Therapies
- -
Reverse Luminal Immune Resistant Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 10
- Registration Number
- NCT06731140
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 460
- Registration Number
- NCT06706401
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT
- Conditions
- Interventions
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT06646666
- Locations
- 🇨🇳
Department of Hematology, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
A Phase II Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Gabriel Tinoco
- Target Recruit Count
- 16
- Registration Number
- NCT06528769
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
- Conditions
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Rita Assi
- Target Recruit Count
- 24
- Registration Number
- NCT06484920
- Locations
- 🇺🇸
Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
🇺🇸Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States
Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 58
- Registration Number
- NCT06439888
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
🇫🇷Centre Léon Bérard, Lyon, France
A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
- Conditions
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 32
- Registration Number
- NCT06371274
- Locations
- 🇨🇳
The first affiliated hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, P.R. China, China
Comparison of Quality of Life in Moderate Acne Vulgaris Patients Based on Acne-QoL-INA Using Standard Therapy With and Without Acne Lesions Extraction
- Conditions
- Interventions
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Indonesia University
- Target Recruit Count
- 40
- Registration Number
- NCT06181838
- Locations
- 🇮🇩
Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo, Jakarta Pusat, DKI Jakarta, Indonesia
Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 21
- Registration Number
- NCT05999812
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL
- Conditions
- Interventions
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Target Recruit Count
- 15
- Registration Number
- NCT05497310
- Locations
- 🇲🇽
Hopsital Universitario Dr. Jose E. Gonzalez, Centro Universitario contra el Cancer, Monterrey, Nuevo Leon, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.